Roche long-acting dual-specific antibody Phase 3 clinical results actively treat specific macular degeneration patients

nAMD affects about 20 million people worldwide and is the main cause of blindness among people aged 60 and over.
current standard treatment is the injection of drugs that inhibit endothor endosthort growth factors (VEGF), which can significantly reduce vision loss caused by nAMD.
, VEGF is not the only factor that causes disease to occur and develop.
patients who have been treated with anti-VEGF monotherapy usually need to go to an ophthalmologist every month for eye injections.
press release, faricimab is the first dual-specific antibody designed for the eye.
it targets two different paths, Ang-2 and VEGF-A, which affect vision by disrupting the stability of blood vessels by causing new leakage blood vessels to form and increasing inflammation.
by blocking both path paths, faricimab is designed to stabilize blood vessels and may lead to better long-term vision outcomes for people with retinal disease.
TENAYA and LUCERNE were two identical randomized double-blind, global Phase 3 clinical studies that assessed the efficacy and safety of faricimab compared to VEGF inhibitor activity control in 1329 nAMD patients.
of the study was the average change in the Best Corrective Vision (BCVA) score from baseline to week 48.
two studies reached their primary endpoint, with patients treated with faricimab achieving non-inferior results compared to the active control group (injected every 8 weeks).
half (45%) of patients in the two studies received faricimab treatment every 16 weeks in the first year, the first time an eye injection drug treated with namAMD has reached such a long duration in Phase 3 clinical trials.
, Roche's chief medical officer and head of global product development, said: "These results show the potential of faricimab as an innovative drug type that can extend the interval between treatment for patients with nAMD.
we have observed positive and consistent results in four Phase 3 clinical trials of faricimab treatment for nAMD and diabetic macular edema.
we look forward to submitting this data to regulators around the world to bring this promising treatment option to patients as soon as possible.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
resources: s faricimab meets primary in in global phase III studies and shows potential to extend time between treatment up to 16 weeks for people with neovascular age-related macular degeneration. Retrieved January 25, 2021, from